PRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 is a Phase 1/2,...
Hence then, the article about taiho oncology and cullinan therapeutics announce pivotal rezilient1 phase 1 2 data published in the journal of clinical oncology was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology )
Also on site :
- Driver dies in fiery freeway crash on Christmas Eve near Sacramento
- 2 people hurt in plane crash into North Sacramento field
- Trump’s Christmas Eve calls with children asking about Santa’s whereabouts are steeped in partisan politics